Association between [CD4.sup.+] T cells ATP levels and disease progression in patients with non-small cell lung cancer

Introducing the exploration of stimulated [CD4.sup.+] cells adenosine triphosphate ([sATP.sup.CD4]) levels for immune monitoring post non-small cell lung cancer (NSCLC) chemotherapy, the present study aimed to investigate its efficacy in gauging the potential risk of disease progression (PD) in patients with NSCLC. Therefore, a total of 89 patients with advanced NSCLC, who underwent chemotherapy between August 15 2022 and August 30 2023 at the Fifth Affiliated Hospital of Guangzhou Medical University (Guangzhou, China), were retrospectively studied. Patients were divided into the PD (n=21) and disease stability (non-PD; n=68) groups and their clinical data were compared. The thresholds for predicting PD were identified using receiver operating characteristics (ROC) curves. Multivariate logistic regression analysis was carried out to assess the association between peripheral blood markers and the incidence of PD. Therefore, post-chemotherapy, significant differences in white blood cell count, non-stimulated [CD4.sup.+] cells ATP and [sATP.sup.CD4] levels were obtained between patients in the PD and non-PD groups (P